Abstract: Nanodiamonds having a positive ?-potential of at least 1 mV for use in sequestration of at least one FGF family member in organisms in vivo and in vitro. It has been found that nanodiamonds with a positive ?-potential show an extremely strong and selective binding to FGF family members, thus leading to their usability in the treatment of diseases related to aberrant FGF-FGFR signalling and/or interaction.

Abstract: The invention provides an isolated thermostable polypeptide possessing FGF2 activity and having at least 85% sequence identity to SEQ ID NO: 2 (FGF2 wt) or a functional fragment thereof, and comprising at least one amino acid substitution R31L and the use thereof in the cell biology research, regenerative medicine and related medical applications or cosmetics. Further it discloses a culture medium comprising subjected FGF2 suitable for culturing a human pluripotent stem cells involving both human embryonic stem cells and induced pluripotent stem cells.

Abstract: An e-charger includes a motor case that encases the motor and an outer housing that houses the motor case. The e-charger additionally includes a cooling system with passages cooperatively defined by the outer housing and the motor case. First and second longitudinal passages extend between the first and second ends of the motor, and a second longitudinal passage extends between the second and first ends of the motor. The end passage fluidly connects the first and second longitudinal passage. The cooling system is configured for directing flow of the coolant from the inlet, through the first longitudinal passage in a first longitudinal direction with respect to the axis, through the end passage, and back through the second longitudinal passage in a second longitudinal direction with respect to the axis.

Abstract: An e-charger includes a motor case that encases the motor and an outer housing that houses the motor case. The e-charger additionally includes a cooling system with passages cooperatively defined by the outer housing and the motor case. First and second longitudinal passages extend between the first and second ends of the motor, and a second longitudinal passage extends between the second and first ends of the motor. The end passage fluidly connects the first and second longitudinal passage. The cooling system is configured for directing flow of the coolant from the inlet, through the first longitudinal passage in a first longitudinal direction with respect to the axis, through the end passage, and back through the second longitudinal passage in a second longitudinal direction with respect to the axis.

Abstract: A compressor device includes a housing with a cavity. The compressor device includes a rotating group supported for rotation within the housing. The rotating group includes a shaft that supports a compressor wheel proximate a first end of the shaft. A second end of the shaft extends away from the compressor wheel through the cavity of the housing. The compressor device further includes a moisture evacuation system configured to remove airborne moisture from the compressor device. The moisture evacuation system includes a shaft passage extending through the second end of the shaft and a housing passage extending through an outer wall of the housing. The shaft passage is fluidly connected to the cavity. The housing passage is fluidly connected to the shaft passage. The moisture evacuation system is configured to direct the airborne moisture from the cavity, through the shaft passage, and out of the housing via the housing passage.

Abstract: In a turbocharged internal combustion engine (ICE) system, a catalytic treatment device receives exhaust gases from the ICE after they have passed through the turbocharger turbine. The system includes a secondary air pump (SAP) for injecting pressurized air into the exhaust gases ahead of the catalytic treatment device. The SAP is a single-stage centrifugal compressor that includes an air recirculation passage for causing a first portion of the air pressurized by the SAP to be continuously recirculated back to the inlet of the SAP, which is effective for heating the air in the volute of the SAP. A second portion of the pressurized air, having thereby been heated, is injected into the exhaust gases proceeding toward the catalytic treatment device.

Abstract: A compressor device includes a housing with a cavity. The compressor device includes a rotating group supported for rotation within the housing. The rotating group includes a shaft that supports a compressor wheel proximate a first end of the shaft. A second end of the shaft extends away from the compressor wheel through the cavity of the housing. The compressor device further includes a moisture evacuation system configured to remove airborne moisture from the compressor device. The moisture evacuation system includes a shaft passage extending through the second end of the shaft and a housing passage extending through an outer wall of the housing. The shaft passage is fluidly connected to the cavity. The housing passage is fluidly connected to the shaft passage. The moisture evacuation system is configured to direct the airborne moisture from the cavity, through the shaft passage, and out of the housing via the housing passage.

Abstract: An e-charger includes a shaft supported for rotation about an axis. The e-charger also includes a compressor wheel that is attached to the shaft. The e-charger further includes an electric motor configured to drive the shaft and the compressor wheel in rotation. Also, the e-charger includes a housing that houses the electric motor and at least part of the shaft. Moreover, the e-charger includes a dampening system incorporated in the housing and configured to dampen loads transferring through the housing. The dampening system includes at least one solid-state dampener that is resiliently flexible, and the dampening system includes at least one fluid viscous dampener.

Abstract: An e-charger includes a motor case that encases the motor and an outer housing that houses the motor case. The e-charger additionally includes a cooling system with passages cooperatively defined by the outer housing and the motor case. First and second longitudinal passages extend between the first and second ends of the motor, and a second longitudinal passage extends between the second and first ends of the motor. The end passage fluidly connects the first and second longitudinal passage. The cooling system is configured for directing flow of the coolant from the inlet, through the first longitudinal passage in a first longitudinal direction with respect to the axis, through the end passage, and back through the second longitudinal passage in a second longitudinal direction with respect to the axis.

Abstract: An e-charger includes a shaft supported for rotation about an axis. The e-charger also includes a compressor wheel that is attached to the shaft. The e-charger further includes an electric motor configured to drive the shaft and the compressor wheel in rotation. Also, the e-charger includes a housing that houses the electric motor and at least part of the shaft. Moreover, the e-charger includes a dampening system incorporated in the housing and configured to dampen loads transferring through the housing. The dampening system includes at least one solid-state dampener that is resiliently flexible, and the dampening system includes at least one fluid viscous dampener.

Abstract: Nanodiamonds having a positive ?-potential of at least 1 mV for use in sequestration of at least one FGF family member in organisms in vivo and in vitro. It has been found that nanodiamonds with a positive ?-potential show an extremely strong and selective binding to FGF family members, thus leading to their usability in the treatment of diseases related to aberrant FGF-FGFR signalling and/or interaction.

Abstract: The invention provides an isolated thermostable polypeptide possessing FGF2 activity and having at least 85% sequence identity to SEQ ID NO: 2 (FGF2 wt) or a functional fragment thereof, and comprising at least one amino acid substitution R31L and the use thereof in the cell biology research, regenerative medicine and related medical applications or cosmetics. Further it discloses a culture medium comprising subjected FGF2 suitable for culturing a human pluripotent stem cells involving both human embryonic stem cells and induced pluripotent stem cells.

Abstract: The invention provides a method of determination of diagnosis and prognosis of B-cell chronic lymphocytic leukemia from a biological sample collected from the body of a patient, wherein the status of Wnt/PCP signaling pathway is determined. Within the framework of the present invention the relation of CLL and molecular signaling pathway Wnt/PCP the components of which are markedly up-regulated in B-lymphocytes of the patients suffering from CLL was identified. The status of the Wnt/PCP signaling pathway can be determined, e.g., by the determination of the expression of components of said signaling pathway or by the determination of migration of CLL cells in the gradient of a chemokine in the presence of the ligand of said signaling pathway. The invention also relates to suitable oligonucleotides for use in the method of determination of expression of the signaling pathway components.

Abstract: The invention provides a method of determination of diagnosis and prognosis of B-cell chronic lymphocytic leukemia from a biological sample collected from the body of a patient, wherein the status of Wnt/PCP signaling pathway is determined. Within the framework of the present invention the relation of CLL and molecular signaling pathway Wnt/PCP the components of which are markedly up-regulated in B-lymphocytes of the patients suffering from CLL was identified. The status of the Wnt/PCP signaling pathway can be determined, e.g., by the determination of the expression of components of said signaling pathway or by the determination of migration of CLL cells in the gradient of a chemokine in the presence of the ligand of said signaling pathway. The invention also relates to suitable oligonucleotides for use in the method of determination of expression of the signaling pathway components.

Abstract: Novel inhibitors of FGFR3 signaling having a structure shown as Formula 1 and a method of inhibiting FGFR3 signaling by administering a quantity of the inhibitor, or pharmaceutical equivalent, analog and/or salt thereof, to a mammal are disclosed.